Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

InMed Pharmaceuticals (INM) Operating Margin: 2022-2025

Historic Operating Margin for InMed Pharmaceuticals (INM) over the last 4 years, with Sep 2025 value amounting to -162.54%.

  • InMed Pharmaceuticals' Operating Margin fell 2535.00% to -162.54% in Q3 2025 from the same period last year, while for Sep 2025 it was -167.40%, marking a year-over-year decrease of 2108.00%. This contributed to the annual value of -160.77% for FY2025, which is 1750.00% up from last year.
  • As of Q3 2025, InMed Pharmaceuticals' Operating Margin stood at -162.54%, which was down 16.52% from -139.49% recorded in Q2 2025.
  • InMed Pharmaceuticals' 5-year Operating Margin high stood at -20.99% for Q2 2023, and its period low was -1,266.61% during Q2 2022.
  • Its 3-year average for Operating Margin is -162.31%, with a median of -158.54% in 2024.
  • Its Operating Margin has fluctuated over the past 5 years, first skyrocketed by 124,562bps in 2023, then tumbled by 13,755bps in 2024.
  • Quarterly analysis of 4 years shows InMed Pharmaceuticals' Operating Margin stood at -471.26% in 2022, then surged by 33,862bps to -132.64% in 2023, then crashed by 7,012bps to -202.75% in 2024, then plummeted by 2,535bps to -162.54% in 2025.
  • Its Operating Margin was -162.54% in Q3 2025, compared to -139.49% in Q2 2025 and -169.43% in Q1 2025.